8 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award
The American Society of Hematology HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award will contribute to the development of the next generation of hematologists by supporting talented medical students and residents to conduct hematology research. The award program has the following objectives:
1. Support the conduct of hematology research by medical students and residents.
2. Introduce medical students and residents to the hematology research community.
3. Encourage medical students and residents to continue research careers in hematology.
The HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award is intended for medical students and residents (residents are defined as trainees who have not yet entered a hematology-related training program) in the United States, Canada, or Mexico with an interest in hematology research. The award will provide the recipient with a $5,000 stipend to conduct either a short hematological research project for a maximum of three months, or a long hematological research project between three and 12 months. The stipend will be distributed in installments, the last of which is dependent upon the receipt of the final report submitted by the recipient. All recipients will also receive $1,000 each year for two years to support attendance at the ASH Annual Meeting.
Applications are due February 21, 2014
Notification of awards May 2014
Travel Award check requests form due for first ASH Annual Meeting October 15, 2014
Short project final report due October 1, 2014
Long project final report due August 1, 2015
Travel Award check request form due for second ASH Annual Meeting October 15, 2015
Eligible applicants must:
• Submit a complete application form.
• Be a MD or DO medical student in an LCME (or its equivalent) accredited institution in the United States, Canada, or Mexico.
• Be enrolled in an ACGME or RCPSC (or their equivalent) accredited training programs in the United Stated, Canada, or Mexico and not yet entered into a hematology-related training program.
• Be enrolled and active in an educational program at the time of application and for the duration of the award term.
• Be working on a hematological project (i.e., adult hematology, pediatric hematology/oncology, hematopathology, blood banking/transfusion medicine), in either laboratory research or clinical investigation for the duration of the award term.
• Have a home research mentor who is a member in good standing of ASH at the time the application is submitted and remain a member of ASH for the duration of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award term.
Fellows, graduate students (including medical students who are in a combined medical or scientific masters program), MD/PhD students, PhD students, medical students or residents who have already earned a PhD in a bio-medical field, and individuals not enrolled in an educational program are ineligible for the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award.
If you have any questions or require any additional information regarding the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award, please contact email@example.com.
American Society of Hematology Clinical Research Training Institute
The ASH Clinical Research Training Institute is a unique year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers and offers a broad education about clinical research methods, research collaborations, statistical analysis, and managing the demands of family and career. The goal of ASH’s Clinical Research Training Institute is to produce a group of researchers armed with ideas for clinical hematology research and the tools and access to resources to make their ideas a reality.
The Clinical Research Training Institute begins with a mandatory week-long summer workshop, to be held from August 2 through August 8, 2014 in La Jolla, CA. The workshop focuses on the foundation, methodologies, and application of patient-oriented clinical research. Participants are matched with workshop faculty members and a small group, which provide participants with intensive exposure to mentorship and networking resources. Throughout the week, participants further develop their own proposed patient-oriented clinical research projects, refining and revising their plans through interaction with faculty and peers.
Each day of the summer workshop is divided into didactic sessions and small group meetings. The mornings are dedicated to lectures on patient-oriented clinical research methodology and related topics, while in the afternoons participants meet with their workshop mentors and other faculty, including biostatisticians, to work on protocol development. Informal presentations by leaders in hematology clinical research take place in the evenings.
In addition to the summer workshop, two subsequent mandatory sessions, the first at the ASH annual meeting and the second on the third Thursday in May at ASH Headquarters in Washington, DC, provide an opportunity for further interaction and mentoring throughout the year. By applying for the Clinical Research Training Institute, you agree to participate in all three segments of the program, if accepted.
There is no fee to apply to the program, and ASH will pay for the participants’ travel expenses to the summer workshop and spring meeting. Travel to and expenses at the annual meeting are the responsibility of the participant and/or their academic institution.
Highlights of the 2014 summer workshop curriculum include:
• Advantages and disadvantages of observational studies and meta-analysis
• Advice for forming and sustaining a multi-disciplinary clinical research team including basic science colleagues
• Tools for assessing the quality of clinical research in your field
• Advice on using mentoring and networking to your advantage
• Overview of the design, conduct, analysis, and interpretation of epidemiologic studies of diseases in humans
• Strategies for securing research funding from NIH institutes and foundations supporting hematology research
• Introduction to skills necessary for presenting your work to diverse audiences
• Advice on preparing research results for publication
• Overview of basic statistical terms, sample size calculation, and interpretation of results in clinical trials
• Advice on successfully interfacing with industry while maintaining research independence
• Application of translational laboratory studies to facilitate early phase I/II clinical trials
• Overview of regulatory rules governing clinical trials
• Advice on strategies for successful collaborative research in cooperative groups by junior faculty
• Formal planning of career development and aims for a successful K23, K08 application, or similar award application
• The ABCs of the genome for clinical researchers
Eligibility Review Due January 8, 2014
Application Deadline March 28, 2014
Finalists Notified June 2014
Summer Workshop August 2 - August 8, 2014
Follow-up Meeting December 2014
Final Class May 14, 2015
All eligibility review and application submissions will be sent a confirmation email. If you do not receive a confirmation email, please contact the ASH Training Coordinator at firstname.lastname@example.org, or at 202-552-4928.
The CRTI is geared toward trainees and early career faculty members in adult and pediatric hematology, hematology/oncology and hematology-related programs at academic medical centers. Eligibility criteria include:
• CRTI applicants are required to be members of ASH in good standing at the time of the eligibility review form submission, and for the duration of the CRTI program. If your 2014 dues have not been paid by 11:59 pm, Eastern, March 1, 2014, your application will be deemed ineligible. To verify your membership status, please log on to the membership section of the ASH website.*
• North American (United States, Canada, Mexico) applicants who at the time of their application AND for the duration of the CRTI program are in hematology-related fellowship training OR are junior faculty who have completed their fellowship training within the past three years. Fellowship training is defined as any sub-specialty training in hematology irrespective of whether this training is concurrent with another training program. The first faculty position is defined as the first position as an instructor (or equivalent) or assistant professor in a hematology-related discipline irrespective of whether the applicant has held a previous faculty position in a field unrelated to hematology.
• International fellow applicants who at the time of the application have received their MD within the past 12 years. OR international faculty applicants who at the time of the application have completed their fellowship training within the past five years.
• Agreement to participate in all of CRTI. Those who are chosen for CRTI are required to attend all parts of the three-part program: 1) the 2014 Summer Workshop; 2) the follow-up program that takes place at the 2014 ASH Annual Meeting; and 3) the one-day Final Class meeting held on May 14, 2015 in Washington, DC.
• Fluency in English.
• Applicants who have been accepted to the Translational Research Training in Hematology (TRTH) program are not eligible to apply for the CRTI program until after the TRTH term has been completed.
• Applicants who have been granted an ASH Scholars Award are not eligible to apply for CRTI during the research period of the awarded project.
• Applicants in their final year of training who plan to transition to another institution the following year are eligible to apply for CRTI but must state the feasibility of completing their proposed research project at the new institution. A support letter from the new institution must be provided in addition to one from the current institution.
• Studies submitted to CRTI must directly involve clinical observation of human subjects. Research projects must include the development or study of new diagnostic methods, therapies, and/or outcome measures that ultimately will benefit patients with hematologic disorders.
• Studies that will be open to enrollment before September 2014 are not eligible as are studies which will have obtained Institutional Review Board approval by the date of the CRTI.
• Studies that are exclusively laboratory based are not appropriate.
* If you need assistance with your username and password, please contact an ASH Customer Relations Representative at email@example.com.
Eligibility Review Form Requirements
Eligibility Review Forms for the 2014 application cycle will be due by 11:59 pm Eastern on January 8, 2014. Those who have fulfilled the eligibility requirements will be invited to submit a full application. An email from ASH will be sent to the applicant within one business day of receiving the application to confirm receipt. If an email is not received, the applicant should notify ASH staff immediately. Failure to notify ASH could result in the eligibility review form not being reviewed.
If you have any questions or require any additional information regarding the ASH Clinical Research Training Institute, please contact firstname.lastname@example.org.
American Society of Hematology Research Training Award for Fellows
Audience: Junior Investigator award for second and third-year fellows in the United States or Canada.
Award Amount: $55,000
Purpose: To allow fellows in training the benefit of protected time for research for one year
Audience: Senior Investigator award for fourth and fifth-year fellows in the United States or Canada
Award Amount: $55,000
Purpose: To allow fellows in training the benefit of protected time for research for one year
The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, or other hematology-related training programs to pursue a career in academic hematology. The RTAF awards $55,000 to fellows in training so they will have protected time for research and is to be used primarily for salary support for the applicant. Awards are targeted to two separate groups of researchers: a Junior Investigator RTAF for second and third-year fellows (apply in years one or two of fellowship) and a Senior Investigator RTAF for fourth or fifth-year fellows (apply in years three or four of fellowship).
Up to six awards of $55,000 each will be given each year.
The goals of this program are to:
• Encourage and enable fellowship programs to provide time for research (clinical, basic science, or translational).
• Promote mentorship of hematology trainees by outstanding faculty members.
• Produce, on a yearly basis, clinician scientist candidates for academic positions.
• Provide bridging funds for trainees who need more time to generate sufficient expertise to be competitive when applying for K award funding.
The ASH Research Training Award for Fellows will grant $55,000 for a one-year period to two groups of fellows. The Junior Investigator RTAF is for second- and third-year fellows (at the time of the award), and the Senior Investigator RTAF is for fourth- or fifth-year fellows (at the time of the award) who are not yet eligible for the ASH Scholar Awards (fellow category) in the United States or Canada. Eligibility will begin on the first day of fellowship and go until five years from that date, with exceptions made for leaves of absence. Assistant professors are not eligible to apply.
The Research Training Award for Fellows is intended to be used primarily for salary support for the applicant. Salary includes benefits provided by applicant's institution for up to 15% of the total award amount. Additionally, up to $5,000 of the award money may be allocated for research supplies and reagents, and up to $1,000 may be allocated for travel to the ASH annual meeting (no other meetings are eligible for this allocation). Each of the non-salary support portions of the proposed budget must be accompanied by a clear justification.
Awards will be activated on July 1 and conclude on June 30 of the year following activation. Monies cannot be used toward salary/benefits for the mentor or toward an institution's overhead or indirect costs. Payments will be made to the appropriate financial officer of the institution.
All letter application submissions will be sent a confirmation email. If you do not receive a confirmation email, please contact the ASH Training Coordinator at email@example.com, or at 202-776-0544.
Applications due (received by 11:59 PM ET) January 15, 2014
Finalists interviews by study section in Washington, DC April 2014
Award notification May 2014
Award activation July 1, 2014
RTAF applicants are required to be members of ASH in good standing at the time of application, and for the duration of the RTAF program. If your 2014 dues have not been paid by 11:59 pm, Eastern, January 15, 2014, your application will be deemed ineligible. New Associate Membership applications should be submitted no later than December 1, 2013 to be processed.
To verify your membership status, please log on to the membership section of the ASH website. If you need assistance with your username and password, please contact an ASH Customer Relations Representative at firstname.lastname@example.org.
Applications for the 2014 award cycle must be received by 11:59 PM ET on January 15, 2014.
Junior Investigator Award
First and second-year fellows may apply to fund research in years two or three of fellowship. Eligible applicants must propose research focused on a hematologic condition (solid tumor projects are not eligible).
At the time of application, the applicant must:
• Possess an MD or DO. MD-PhDs, DO-PhDs and PhDs are not eligible unless the PhD is in a non biomedical field. National Institute of Health employees are not eligible for this award.
• Continue to maintain ASH membership and remain members in good standing of ASH for the duration of the RTAF award term.
• Be a first or second-year fellow in an ACGME or RCPSC accredited hematology, hematology/oncology, or hematology-related fellowship program in the United States or Canada. Eligibility will begin on the first day of fellowship and go until five years from that date, with exceptions made for leaves of absence. Assistant professors are not eligible to apply.
• Plan to pursue an investigative career in hematology research.
• Have a mentor who is an ASH member at the time the application is submitted and remain members of ASH for the duration of the RTAF award term. If the mentor is not in a hematology related field then a supporting letter from an ASH member is required. ( Additional mentors can be recommended by members of the study section)
• Have clear and documented support of an established mentor. This person should have funding (funding may be NIH, federal, foundation, or private) or be recognized through national clinical leadership (if the project is clinical). The mentor must remain funded during the award period.
• Provide documented support from the program director for dedicated research time during the award period.
• Secure a document from appropriate institutional leaders that states that at least 75 percent of the applicant's full-time professional efforts will be devoted to research during the funded period.
• Not hold a position as an Assistant Professor or Lecturer.
At the time of the award (July 1) the applicant must:
• Have completed one year of clinical training within a hematology, hematology/oncology, or hematology-related training program in the United States or Canada.
• Be a second or third-year fellow in an ACGME or RCPSC accredited hematology, hematology/oncology, or hematology-related training program in the United States or Canada.
• Continue to maintain ASH membership. Eligibility will begin on the first day of fellowship and go until five years from that date, with exceptions made for leaves of absence. Assistant professors are not eligible to apply.
• Not have any other career-development funding during the award period. Including but not limited to foundation and NIH career development, K12, K23, K01 K 8, T32), ASCO YIA, Leukemia and Lymphoma Society Clinical Scholar awards, etc.
• The RTAF is to be the recipient's main source of salary support. In the event that the recipient's salary is not fully covered by the Research Training Award for Fellows, supplementary funding from non career development awards or grants may be used to pay the balance of the recipient's salary.
• Not be accepted in the Clinical Research Training Institute or the Translational Research Training in Hematology programs during the research period of the awarded project.
• Not have accepted an ASH Scholar Award.
Criteria for selection include:
• A focus on hematology research.
• The qualifications and experiences of the applicant. Factors to be considered include, but are not limited to, the potential for future independent clinical or laboratory investigation and commitment to a career in hematology research.
• Quality of the mentor and the plan for mentor/applicant interaction and career development.
• The significance, feasibility, and originality of the proposed hypothesis, research, and methodology.
• Availability of institutional resources to support the proposed project.
Senior Investigator Award
Third and fourth-year fellows may apply to fund research in years four and five of fellowship. Eligible applicants must propose research focused on a hematologic condition (solid tumor projects are not eligible). Eligibility will begin on the first day of fellowship and go until five years from that date, with exceptions made for leaves of absence. Assistant professors are not eligible to apply.
• Continue to maintain ASH membership and remain members of ASH for the duration of the RTAF award term.
• Be in the third or fourth-year of a hematology, hematology/oncology, or hematology-related fellowship in the United States or Canada.
• Have clear and documented support of a funded mentor (funding may be NIH, federal, foundation, or private) or have a mentor recognized through national clinical leadership (if the project is clinical). The mentor must remain funded during the award period.
• Have a mentor who is an ASH member at the time the letter of intent is submitted, and remain members of ASH for the duration of the RTAF award term. If the research mentor is not in a hematology related field then a supporting letter from an ASH member is required. (Additional mentors can be recommended by members of the study section).
• Secure a document from appropriate institutional leaders that states that at least 75 percent of the applicant’s full-time professional efforts will be devoted to research during the funded period.
• Have completed two years of training within a hematology, hematology/oncology, or hematology-related training program in the United States or Canada.
• Be a fourth or fifth-year trainee in a hematology, hematology/oncology, or hematology-related training program in the United States or Canada. Eligibility will begin on the first day of fellowship and go until five years from that date, with exceptions made for leaves of absence. Assistant professors are not eligible to apply.
• Continue to maintain ASH membership.
• Not have any other career-development funding during the award period. Including but not limited to foundation and NIH career development (K12, K23, K01 K08, T32) ASCO YIA, Leukemia and Lymphoma Society Clinical Scholar awards, etc.
• The RTAF is to be the recipients' main source of salary support. In the event that the recipient's salary is not fully covered by the Research Training Award for Fellows, supplementary funding from non career development awards or grants may be used to pay the balance of the recipients' salary.
• The qualifications and experiences of the applicant. Factors to be considered include, but are not limited to the potential for future independent investigation and commitment to a career in hematology research.
Please Note: Any application which does not follow the stated requirements, includes additional documents outside of the required documents, is not formatted correctly, is lacking information, has incorrect information, or is lacking required documents as outlined in this document, will be deemed ineligible and will not be reviewed by the study section.
There are no appeals, or consideration for additional or further review once an application has been determined to be ineligible.
Questions regarding this application and the ASH Research Training Award for Fellows should be directed to the ASH Training Manager, at email@example.com or 202-776-0544.
American Society of Hematology Minority Medical Student Award Program
Deadline to request a mentor for the 2014 MMSAP program is Monday, January 6, 2014.
The Minority Medical Student Award Program (MMSAP) is an 8- to 12-week research experience for students from the United States and Canada in their early years of medical school. As part of this experience, students collaborate with an ASH member who serves as their research mentor. Program participants are also paired with an ASH member who serves as a career-development mentor throughout the participants' medical schooling and residency.
At the end of the research experience, students present their findings at the Promoting Minorities in Hematology Presentations at the ASH annual meeting. After the research year, the students remain involved with ASH throughout medical school and residency to keep them engaged in the study of hematology and to help them gain valuable knowledge in the field. In addition, students who participate in this program may apply to the program for a second summer research experience.
Participants receive the following support:
• A stipend of $5,000
◦ $2,500 at the start of the research experience, $1,250 during the middle, and $1,250 at the completion of the research experience
• A $2,000 allowance for travel to the ASH annual meeting held in early December
◦ $1,000 for attending the annual meeting
◦ $1,000 for a short presentation about the research experience at a special reception
• Complimentary subscriptions to Blood, the journal of the American Society of Hematology, as well as The Hematologist, the Society's newsletter, during medical school and residency years.
• The guidance of a research and career-development mentor
Request a Mentor Deadline September- January 6, 2014
Application Deadline March 10, 2014
Award Winners Notified Late April
For the purposes of this program, minority is defined as individuals from racial and ethnic groups that have been shown to be underrepresented in health-related sciences in the United States and Canada, including American Indians or Alaska Natives, Blacks or African Americans, Hispanics or Latinos, Native Hawaiians or Other Pacific Islanders, African Canadians, Innuit, and First Nation Peoples. Thus, applicants must self-identify, and participants are drawn from this pool.
Applicants must be within their first or second year of medical school, enrolled in a MD, DO, or MD/PhD medical school programs and be citizens or permanent residents of the United States or Canada.
Request a Mentor:
◦ The application deadline is January 6, 2014
◦The application deadline is March 10, 2014
• Note about letters of recommendation
◦ Applicants will need to submit three letters of recommendation:
1. Letter from the dean of your medical school
2. Letter from an advisor or medical school instructor
3. Letter of endorsement from your research mentor
• Applicants must identify a research mentor on the application; the research mentor must be a member of ASH.
◦ If needed, ASH will assist applicants with finding a research mentor through the Request a Mentor process.
Evaluation, Selection, and Notification
• Applications submitted by the deadline will be reviewed by the Committee on Promoting Diversity. Applicants will be evaluated on the following criteria:
◦ Research (academic potential)
◦ Research mentor/proposed project
◦ Interest in hematology
Applicants selected for participation and their mentors will receive official notification of acceptance by late April.
Questions or requests for additional information regarding the MMSAP can be directed to the ASH Awards Department at firstname.lastname@example.org or by phone at 202-776-0544.
American Association for Cancer Research-Millennium Fellowship in Lymphoma Research
Application deadline: December 11, 2013, at noon, Eastern Time
Decision date: March 2014
Annual Grants Reception and Dinner at AACR Annual Meeting 2014: April 8, 2014 - Grant recipient must attend the Grants Reception and Dinner and formally accept the grant. Grant funds may be used to support the grantee’s attendance at this Annual Meeting; complimentary registration will be provided.
Start of grant term: July 1, 2014
The AACR-Millennium Fellowship in Lymphoma Research represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct lymphoma-based research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to lymphoma.
The fellowship provides a one-year grant of $55,000 to support the salary and benefits of the fellow while working on mentored lymphoma-related research. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project and other research expenses.
It is anticipated that three fellowships will be funded.
Applicant Eligibility Criteria
Applicants must have a medical and/or doctoral degree (including Ph.D., M.D., D.O., D.C., N.D., D.D.S., D.V.M., Sc.D., D.N.S., Pharm.D., or equivalent doctoral degree) in a related field and not currently be a candidate for a further doctoral or professional degree.
At the start of the grant term on July 1, 2014, applicants must:
Be in the first five years of a postdoctoral or clinical research fellowship (i.e., must have started fellowship no earlier than July 2, 2009, and no later than July 1, 2014)
Work under the auspices of a mentor at an academic, medical, or research institution within the United States. There are no citizenship requirements; however, an applicant who is not a U.S. citizen or permanent resident, by submitting an application for this grant, assures that his/her visa status will provide sufficient time to complete the project and grant term within the United States.
For applicants possessing an M.D., clinical training time with no research involvement (e.g., residency training) is not included against the eligibility limit. Parental leave or other well justified leave from mentored research training for pressing personal or family situations of generally less than 12 months duration is also not included against the eligibility limit for all applicants.
Applicants whose experience exceeds the maximum but who believe they are eligible (e.g., residency training, some of their mentored research experience was in a field other than cancer research or there was a break in their career as described above) should contact AACR before submitting an application to verify their eligibility. Applicants who believe that they are at the level of postdoctoral or clinical research fellow, but hold a different title (e.g., M.D. with an instructor title), may be eligible and should contact AACR before submitting an application.
Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible.
AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR associate membership by Friday, December 13, 2013. The application will be applied to 2013 membership dues.
All applicants with questions about eligibility should contact AACR before submitting an application.
Research Project Criteria
Research projects must have direct applicability and relevance to lymphoma. They may be in any discipline of basic, clinical, translational or epidemiological research but must fall within one or any combination of the following specific areas: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma; and/or Non-Hodgkin Lymphomas.
Request for Applications: Leukemia & Lymphoma Society Screen to Lead Program
The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and optimization of small molecules into drug-like compounds suitable for in vivo testing in a disease-relevant model that can be used for further preclinical proof-of-concept testing of the new drug target. Last year, the first year of this new funding mechanism, 6 projects were chosen for funding by an acclaimed peer review panel. This year, new laboratories/projects will be selected to participate in this model of collaboration whereby LLS, grantee, sponsoring institution and appropriate contract service organizations (CROs) or core facilities at academic institutions work together to develop compounds with the potential to change the standard of care for patients with blood cancer. Continued funding/sponsorship will be contingent on available funds and assessments of progress toward the goals outlined in each individual proposal accepted by LLS.
The goal of this RFA is the development of small molecule for in vivo proof of concept studies in disease relevant animal models for hematological malignancies. Proposals should include strong scientific rationale for a new drug target in a hematological malignancy; provide information to assess existing intellectual property or the potential for novel chemical space; demonstrate or explain how a screening assay can be developed to accommodate a high volume of compounds; or indicate how a tractable lead compound can be further developed.
Investigators at academic laboratories are eligible to apply. Investigators must demonstrate that their research environment is equipped and suitable for aspects of the work plan that would be carried out at their facility or in their lab rather than at a CRO. Collaborations between multiple investigators to strengthen the work proposed will be considered favorably, but are not a requirement. Applicants need not be United States (U.S.) citizens nor associated with a U.S.-based institution. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.
APPLICATION and AWARD INFORMATION
LLS plans to sponsor several awards during this year of this program. It is anticipated that each project will be unique and the cost of each work plan variable, depending on the nature of the work required. For this reason, applicants will need to submit a proposed work plan (subject to modification by LLS and collaborators upon review) and a proposed budget with justification for its relationship to the work plan. These factors will be evaluated as part of the peer review application process. As collaborators in CROs or core facilities may conduct the greater portion of the work, LLS will coordinate the appropriate contracting for services according to the work plan. LLS will work with applicants to determine where the work should be conducted and help to manage the process. For any budgeted line items that are specifically related to the PI, for work conducted in their laboratory, indirect costs will be capped at 11.1%. Any new intellectual property created through this collaboration shall be owned and managed by the academic institution. LLS and CRO subcontractors shall assign all ownership rights to the institution. LLS will put in place, as it does with all its grants, an IP policy that must be executed by the researcher and researcher's academic institution at the time the application is submitted.
Applicants should include the following in their application:
Scientific rationale for novel target in hematologic malignancies and summary of supportive data;
Characterization of existing compounds, where appropriate;
A summary of the intellectual property landscape (to the best of knowledge) on the target/chemical space;
Description of unmet medical need, i.e., what therapeutic deficiency will this new drug target address; and
Capabilities of support from laboratory (i.e., describing the level of throughput for assays applicants propose to run in their laboratories)
APPLICATION FORMAT and SUBMISSION
Application templates are web-based and may be obtained on our website at: http://lls.fluxx.io under Screen to Lead Program. Applications are restricted to the capacity of the web forms. The form for budgets allows multi-year entries but only the first year is considered for this award. Please include only costs associated with your institution. Any CRO costs, if needed, will be determined by LLS and added to your budget. If you have had prior discussions with a CRO and have a budget estimate, you are welcome to upload this under the appropriate section but no other supporting documentation is allowed except the signed IP policy which is part of the RFA and must be included with your application.
The cut off for the receipt of applications is on the following date/time schedule:
Deadline: December 15, 2013, 3:00 p.m., ET
Scientific Peer Review Committee: April 2014
Notification of Awards: May 30, 2014
Anticipated Funding Start Date: October 2014
DESCRIPTION of PEER REVIEW PROCESS
Each application will undergo a thorough review that consists of two parts. There will be an internal review by LLS Research staff for compliance with guidelines, eligibility, and responsiveness of the project to the RFA. The internal review may involve additional requests for more detailed information on the project and direct discussions between the PI and LLS Research staff regarding the proposal to assess the appropriateness of the project.
There will be a second review hosted by LLS that is a more extensive external peer review by experts in drug discovery and development, medicinal chemistry, and hematological malignancies.
The application will be assessed upon the following criteria:
Scientific Rationale and Supportive Data
Unmet Medical Need/Scientific Impact
Research Plan & Feasibility
Resources & Qualifications of the PI
American Society of Hematology Mentor Award
Mentorship is one of the most important determinants of a successful career in hematology, yet it is often a component of career development that, while prized by recipients, is rarely rewarded. In recognition of the value the Society places on mentorship, the ASH Mentor Award was created to reward outstanding mentors in the hematology community. Superb mentors from any of the different branches of hematology are eligible for this award, including adult or pediatric hematologists; academic or community practitioners; basic, clinical, or translational researchers; hematopathologists; transfusion medicine specialists; and individuals working in industry or government. It is anticipated that awardees will have had a sustained career commitment to mentoring, a significant positive impact on their mentees' careers, and through their mentees have advanced research and patient care in the field of hematology.
Each year one award in the amount of $5,000 and a plaque will be granted to two outstanding mentors drawn from the areas of basic science, clinical investigation, education, or clinical/community care. (The ASH Mentor Award Study Section reserves the right to not grant awards if no suitable nominations have been submitted.)
This award is based on the training experiences and success of the nominee’s mentees, not the mentor’s personal career achievements. For the purpose of this award, mentoring is defined as the process of guiding, supporting, and promoting the training and career development of others. The key roles of a mentor include, but are not limited to providing:
• Intellectual growth and development
• Career development
• Professional guidance
• Positive role modeling
2014 Selection Process Timeline
Nomination packages due: April 4, 2014
Study section to meet to review scores and decide on recommendations for Awards and Executive Committees: Late April 2014
Final selections will be sent to the ASH Awards Committee and the ASH Executive Committee for final approval: May 2014
Winners notified: June 2014
1. All nominees and nominators must be members of ASH.
2. Nominees of all nationalities and all countries of residence are eligible; however, all application materials must be submitted in English.
3. Nominees may include adult or pediatric hematologists; academic or community practitioners; basic, clinical, or translational researchers; hematopathologists; transfusion medicine specialists; and individuals working in industry or government.
4. Nominees should have a sustained record of mentoring over time.
5. Nominators must be a mentee of the nominee, or colleagues who have personal knowledge of the nominee’s mentoring efforts.
6. Mentees should be actively involved in research, teaching, mentoring, or other leadership activities.
7. The nominator, primary, and secondary mentee must be three individuals.
1. Prior recipients of the ASH Mentor Award are ineligible for future awards.
2. Voting members of the ASH Executive Committee, the ASH Awards Committee or the Mentor Award Study Section are ineligible for a mentor award during their tenure.
3. Self-nominations and posthumous nominations will not be accepted.
4. Recipients of the William Dameshek Prize, Henry M. Stratton Medal, and E. Donnall Thomas Lecture and Prize are ineligible for the year they receive the award.
• Nominations will be due via e-mail no later than 11:59 p.m. (PST)
• Nominations must be submitted electronically to email@example.com
• The file should be named in the following format: Mentor Award [nominee’s] Lastname-Firstname Year.pdf.
• Nominations are reviewed and scored on the following criteria: 1) intellectual growth and development, 2) career development, 3) professional guidance, 4) advocacy, and 5) being a role model. Each of these criteria are scored individually, therefore the nomination and support letters should provide sufficient detail and specific examples that speaks to each of these elements.
• Please be sure to include all necessary documents in the order below in one PDF document; separate e-mails will not be considered.
• Nominations that are not formatted correctly, that contain incorrect documents, or that are missing required documents will not be considered.
Nomination packages must include the following information:
1. The completed nomination form.
2. The nominee's curriculum vitae.
3. Three letters of recommendation.
◦ A letter written by the nominator that summarizes the nominee's impact on the training/careers of his/her mentees.
◦ Two letters written by the primary and secondary mentee (can be a former or current mentee) who can each provide a first-hand account of how the nominee influenced his or her career. Academic, clinical, and educational achievements on the part of the mentee will all be considered important. These mentees must be willing to complete a structured telephone interview about the nominee's mentoring capacity.
◦ Optional: Up to three additional letters of support from junior and senior faculty will be accepted, but are not required. Ideally, at least one letter should be written by a mentee who can provide a first-hand account of how the nominee influenced his or her career. Academic, clinical, educational, and regulatory achievements on the part of the mentee will all be considered as important.
It is suggested that the nominees participate in the process of assembling the nomination package, since their mentoring achievements may have spanned many years, beyond the experience of individual mentees.
Nomination and Selection Process
New- Nominations for both the ASH Honorific Awards and Mentor Awards will now be accepted throughout the year. Any nomination submitted prior to the award deadline will be considered for the current year’s review cycle. Nominations submitted after the award deadline will be considered for the following year’s review cycle.
Nominations may be made by any member of ASH, based on either having been mentored by the nominee or by personal observation of mentoring provided to others by the nominee. Nominators may be mentees of the nominee or colleagues who have personal knowledge of the nominee's mentoring efforts.
The ASH Mentor Award Study Section, which reviews nomination packages, includes, but is not limited to, two members from the ASH Trainee Council, one member from the ASH Educational Affairs Committee, two member from the ASH Awards Committee, one member from the ASH Committee on Practice, and two members from the ASH Committee on Training Programs.
Nomination packages will be forwarded to the Mentor Award Study Section for review. Nomination packages are reviewed and scored by the members of the Study Section on a mentoring score card. Several members of the Study Section review each nomination package.
Nominations are scored based on the Award Criteria and the overall strength of the nomination package. Final selections will be based on a consensus of the entire Study Section. The Study Section will encourage nominators of highly ranked, but unsuccessful, nominees to resubmit their application in subsequent years. Final selections are sent to the ASH Awards Committee and the ASH Executive Committee for final approval by the end of June. Awardees are notified in July.
Questions about the ASH Mentor Award may be directed to firstname.lastname@example.org.
National Blood Foundation Scientific Research Grants Program
All applications must be received at the NBF office by 11:59 pm ET, December 31, 2013. Extensions will not be granted.
Funds are raised annually from corporations, blood centers, foundations and individuals by the NBF for the National Blood Foundation Research and Education Trust Fund (NBFRET) and the NBF. The NBF and NBFRET, which are 501(c)(3) organizations, provide grants for scientific research in the field of transfusion medicine and cellular therapies and support educational initiatives that benefit this community. Since 1985, the NBF has distributed approximately $8 million to 182 early-career scientists. The National Blood Foundation annually awards grants for one or two-year research projects, with a maximum award per grant of $75,000.
NBF is pleased to announce the availability of funding in 2014 for scientific research projects related to transfusion medicine and cellular therapies. NBF will award grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine and cellular therapies. NEW in 2014, patient blood management is introduced as a research content area.
Important areas of research for the grant program include:
Alloimmunization, immune modulation, and tolerance
Animal models for the study of graft-vs-host disease
Biology of autoimmune hemolytic anemia
Autologous and allogeneic stem cell transplants
Detection of residual disease following stem cell transplants
Effects of growth factors in vitro and in vivo
Biochemistry of coagulation factors
Blood group serology
Biochemistry of red cell antigens
Molecular genetics of the blood groups
Studies on Lyme disease, West Nile Virus, SARS and babesiosis and other emerging diseases
Effect of allogeneic transfusion in HIV-infected and immunocompromised patients
Improved detection of transfusion - transmitted diseases
Cell separation, cell culture or expansion studies for cell therapy applications
Development of novel cell therapies or assays to measure cell viability or function
Pilot studies in regenerative medicine
Studies on mechanisms or roles of cells in stem cell transplantation
Studies on cytokines or growth factors involved in stem cell differentiation
NEW!! PATIENT BLOOD MANAGEMENT
Treatment of pre-admission anemia and bleeding tendencies; Intraoperative/postoperative blood recovery; Surgical hemostasis; Appropriate indications for transfusion; Changing physician behaviors; Blood utilization review.
Grants applications are evaluated on the basis of their scientific merit, relevance to and impact on transfusion medicine, focus and appropriateness to the scope of funding, and likelihood of yielding meaningful data.
An applicant must be a doctor (MD or PhD), medical technologist, transfusion medicine or cellular therapies professional. All applicants will be considered regardless of age, race, gender, national origin or religion.
The NBF accepts national and international applicants who are ideally no more than five years post-doctoral training.
Applications for research into innovative and new projects are a priority.
Emphasis is given to applicants who have not previously received an NBF grant.
No candidate is eligible to receive more than two NBF grants for separate projects.
No particular project can be funded more than once.
An application for the same project may be submitted up to three times if not already NBF funded.
Awards will not be made to increase the funding available for currently funded research projects. NBF grants are intended to provide "seed" funding that allows the principal investigator to enhance preliminary data. This data may then be useful in applying for larger grants.
All applicants will be charged an application fee of $150 except for principal investigators who are individual members of the AABB. AABB institutional membership does not qualify. To become an AABB member, please contact AABB's Membership Services at +1.301.215.6489 or email@example.com.
Contact NBF at +1.301.215.6552 or firstname.lastname@example.org.